^
    Back
    Association details:
    Biomarker:ITIH5 overexpression
    Cancer:Bladder Cancer
    Drug Class:CTLA4 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Mol Omics
    Title:

    ITIH5, as a predictor of prognosis and immunotherapy response for P53-like bladder cancer, is related to cell proliferation and invasion

    Published date:
    07/11/2023
    Excerpt:
    In addition, ITIH5 expression was positively correlated with the expression levels of many immune checkpoints, and the high ITIH5 expression group showed better response rates to PD-L1 and CTLA-4 therapies. In short, ITIH5 is a predictor of prognosis and the immunotherapy response for p53-like BLCA and is correlated with tumor immunity.
    DOI:
    10.1039/d2mo00322h